Harlan Robins Sells 10,000 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 10,000 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $15.72, for a total value of $157,200.00. Following the completion of the sale, the insider directly owned 1,169,524 shares of the company’s stock, valued at approximately $18,384,917.28. This represents a 0.85% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website.

Adaptive Biotechnologies Price Performance

NASDAQ:ADPT opened at $15.93 on Friday. Adaptive Biotechnologies Corporation has a fifty-two week low of $6.26 and a fifty-two week high of $20.76. The stock’s 50-day moving average is $16.83 and its two-hundred day moving average is $15.79. The stock has a market cap of $2.45 billion, a PE ratio of -39.82 and a beta of 2.19.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Thursday, February 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.10. Adaptive Biotechnologies had a negative net margin of 21.48% and a negative return on equity of 46.68%. The business had revenue of $71.68 million during the quarter, compared to analyst estimates of $59.38 million. During the same period in the prior year, the firm earned ($0.23) earnings per share. The firm’s revenue was up 51.0% compared to the same quarter last year. On average, equities research analysts anticipate that Adaptive Biotechnologies Corporation will post -0.92 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently weighed in on ADPT shares. Morgan Stanley initiated coverage on shares of Adaptive Biotechnologies in a research note on Monday, December 1st. They issued an “equal weight” rating and a $21.00 price target on the stock. Piper Sandler set a $21.00 target price on Adaptive Biotechnologies in a research report on Friday, February 6th. Wall Street Zen raised Adaptive Biotechnologies from a “hold” rating to a “buy” rating in a research note on Sunday, February 8th. Weiss Ratings reissued a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Wednesday, January 21st. Finally, TD Cowen restated a “buy” rating on shares of Adaptive Biotechnologies in a report on Friday, February 6th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $18.25.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. XTX Topco Ltd bought a new stake in shares of Adaptive Biotechnologies during the 2nd quarter worth $793,000. SG Americas Securities LLC raised its holdings in Adaptive Biotechnologies by 53.2% in the 2nd quarter. SG Americas Securities LLC now owns 37,328 shares of the company’s stock worth $435,000 after acquiring an additional 12,963 shares during the period. Hillsdale Investment Management Inc. acquired a new position in Adaptive Biotechnologies during the 2nd quarter worth $6,618,000. Allianz Asset Management GmbH boosted its holdings in Adaptive Biotechnologies by 305.8% during the third quarter. Allianz Asset Management GmbH now owns 321,774 shares of the company’s stock valued at $4,814,000 after acquiring an additional 242,474 shares during the period. Finally, Envestnet Asset Management Inc. acquired a new stake in shares of Adaptive Biotechnologies in the second quarter valued at about $467,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: Q4 results and revenue beat — Adaptive reported stronger-than-expected Q4 results (EPS beat and revenue +51% YoY), which supports longer-term growth expectations and was a catalyst for bullish analyst notes earlier this quarter. MarketBeat ADPT page
• Positive Sentiment: Analyst backdrop mostly constructive — Multiple firms have buy/overweight ratings and recent price-target increases (consensus “Moderate Buy”), which provides support vs. headline volatility. Analyst coverage summary
• Neutral Sentiment: Short-interest data shows an anomalous 0-share reading and a 0.0 days-to-cover metric — this appears to be a data/reporting artifact rather than a meaningful change in bearish positioning. (No actionable signal until corrected data is posted.)
• Neutral Sentiment: Small institutional activity — several modest new or increased stakes were reported in recent filings; institutional ownership remains high (~99%). These moves are small relative to market cap and unlikely to drive intraday price action. Institutional holdings
• Negative Sentiment: Large CEO selling — CEO Chad Robins has executed multiple large sales, including a 289,024‑share sale on Mar. 2 at ~$15.82 (~$4.57M) and other recent disposals totaling hundreds of thousands of shares; these sizable reductions (one filing showed a ~12.7% position cut) are a near-term negative signal for investor sentiment. CEO sale SEC filing
• Negative Sentiment: Other insider sales — COO Julie Rubinstein sold ~30.9k shares (filings show sales at ~$15.67–$16.00 for ~$485k–$495k), and director/insider Harlan Robins sold multiple blocks (10k and ~14.2k shares). Multiple insider sales in a short window amplify market concern about near-term insider conviction. COO sale SEC filing Harlan sale SEC filing

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.